Delisting risk
INTS · NASDAQ · Biotechnology

Intensity Therapeutics (INTS)

Develops INT230-6, a tumor-injection treatment candidate for solid cancers.

$4.00
Pre-market−0.05 (−1.23%)
At close$4.05(−0.49%)

Something off on this page? Send us feedback.

Next report
Nov 5, 2026
in 63 days
EPS estimate
−$0.94
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.22−$0.22−$0.13−$0.06−$1.69−$0.96−$1.11Pending
Estimate−$0.23−$0.21−$0.06−$0.06−$1.24−$1.19−$0.87−$0.94
Surprise+4.3%−4.8%−116.7%0.0%−36.3%+19.3%−27.2%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.94
Aug 2026−$0.87−$1.11−27.2%
May 2026−$1.19−$0.96+19.3%
Mar 2026−$1.24−$1.69−36.3%
Nov 2025−$0.06−$0.060.0%

The latest year is open to everyone — the 19 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
Jun 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Dec 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 5, 2026−$0.94
Aug 11, 2026−$0.87−$1.11−27.2%−2.1%
May 7, 2026−$1.19−$0.96+19.3%−0.4%
Mar 27, 2026−$1.24−$1.69−36.3%−5.8%
Nov 6, 2025−$0.06−$0.060.0%−6.2%

The latest year is open to everyone — the 19 quarters behind it read with an account.

Sign in
Aug 7, 2025
May 13, 2025
Mar 13, 2025
Nov 13, 2024
Aug 8, 2024
May 9, 2024
Mar 14, 2024
Nov 13, 2023
Aug 14, 2023
Jun 30, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020